Crinetics outlines $600M-$650M 2026 operating expense plan as PALSONIFY launch accelerates
Source: SeekingAlpha
2026-02-26 22:38:23 ET
More on Crinetics Pharmaceuticals
- Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2025 Earnings Call Transcript
- Crinetics Pharmaceuticals, Inc. (CRNX) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Crinetics Pharmaceuticals, Inc. (CRNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Crinetics Pharmaceuticals Q4 2025 Earnings Preview
- Crinetics Pharmaceuticals prices offering at $45.95 per share
Read the full article on Seeking Alpha
For further details see:
Crinetics outlines $600M–$650M 2026 operating expense plan as PALSONIFY launch accelerates
Crinetics Pharmaceuticals Inc.
NASDAQ: CRNX
CRNX Trading
-3.84% G/L:
$36.46 Last:
437,237 Volume:
$37.38 Open:
CRNX Latest News
February 26, 2026 04:05:00 pm
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 05, 2026 04:05:00 pm
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March
CRNX Stock Data
$4,886,200,047
97,468,580
0.1%
86
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
